Target intelligence / Profile preview

Cytochrome b reductase 1 (CYBRD1)

Target
CYBRD1
Molecular classification
Enzyme, Oxidoreductase, Transmembrane protein, Cytochrome b(561) family
01

Overview

Cytochrome b reductase 1 (CYBRD1) is a plasma membrane-associated reductase enzyme, highly expressed on the brush border membrane of duodenal enterocytes in humans. It catalyzes the ascorbate-dependent reduction of ferric (Fe3+) to ferrous (Fe2+) iron, a critical biochemical step for dietary iron absorption. CYBRD1 is a member of the cytochrome b(561) family and is regulated by iron status and hypoxia, mediated by the HIF2 transcription factor. While most studied in intestinal iron metabolism, CYBRD1 is also expressed in other tissues such as lungs, erythrocytes, and breast tissue, where it may contribute to ascorbate metabolism and extracellular oxidoreductase processes. Genetic variation in CYBRD1 influences iron status and may relate to disease states including iron overload syndromes and cancer prognosis.

Other names
Plasma membrane ascorbate-dependent reductase CYBRD1DCYTBFRRS3FLJ23462CYB561A2Duodenal cytochrome bFerric-chelate reductase 3cytochrome b561 family member A22210407P13RikMGC122108CYTBDcytb
02

Mechanism of action

For hypothetical small molecule or biologic targeting, possible mechanisms include: - Inhibition or modulation of ferric reductase activity to alter iron uptake - Modulation of expression for indirect impact on iron absorption

03

Biological functions

Ferric-chelate reductase (Fe3+ to Fe2+ for dietary iron absorption)Ascorbate-dependent reductionPossible cupric (Cu2+) reductase activityPotential role in extracellular ascorbate regeneration
04

Disease associations

Iron metabolism disorders (e.g., Hemochromatosis, Type 1)Iron deficiencyBreast cancer prognosis biomarkerOther iron-related diseases
05

Safety considerations

Disruption of CYBRD1 function may contribute to iron deficiency or overloadPotential impact on systemic iron homeostasis or ascorbate metabolism
06

Interacting drugs

No direct therapeutics targeting CYBRD1 are currently established; iron chelators and iron supplements may influence its substrate or pathway, but are not direct interactors
07

Biomarkers

DCYTB protein levels in breast tissue as a favorable prognostic biomarker in breast cancerSNPs in promoter (e.g., rs884409) affecting iron status

Beyond the preview

Go deeper on Cytochrome b reductase 1 (CYBRD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome b reductase 1 (CYBRD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call